SML3515
Bulevirtide trifluoroacetate
≥98% (HPLC)
别名:
Myrcludex B trifluoroacetate, Myrcludex-B trifluoroacetate, N-Tetradecanoylglycyl-Thr-Asn-Leu-Ser-Val-Pro-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His-Gln-Leu-Asp-Pro-Ala-Phe-Gly-Ala-Asn-Ser-Asn-Asn-Pro-Asp-Trp-Asp-Phe-Asn-Pro-Asn-Lys-Asp-His-Trp-Pro-Glu-Ala-Asn-Lys-Val-Gly-NH2 trifluoroacetate
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C248H355N65O72 · xC2HF3O2
分子量:
5398.86 (free base basis)
NACRES:
NA.77
UNSPSC Code:
12352200
assay
≥98% (HPLC)
form
(Powder or Lyophilized powder or film)
storage condition
desiccated
color
white to off-white
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Bulevirtide is a synthetic lipopeptide derived from the preS1 domain of the Hepatitis B virus (HBV) envelope protein that specifically binds to hepatocytes and efficiently blocks de novo HBV and its satellite virus hepatitis D (HDV) infection both in vitro and in vivo.
HDV and HBV virion entry inhibitor
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
Urban S, Neumann-Haefelin C, Lampertico P
Gut, 70, 1782-1794 (2021)
Bulevirtide for HBV and HDV infections
Yardeni D, Koh C
Drugs Today (Barc), 57(7), 433-448 (2021)
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
Journal of Hepatology, 58(5), 861-867 (2013)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持